Arcutis Biotherapeutics (ARQT) vs Enliven Therapeutics (ELVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Enliven Therapeutics (ELVN) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 100.0% versus a gain of 15.3%. Over five years, ELVN leads with a +177.5% price change compared with +9.9% for ARQT. Arcutis Biotherapeutics is the larger company by market cap ($3.08 billion vs $2.98 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | ELVN |
|---|---|---|
| Share price | $24.49 | $40.63 |
| Market cap | $3.08B | $2.98B |
| 1-day change | +1.32% | -1.76% |
| YTD return | -15.67% | +163.83% |
| 1-year return | +15.30% | +99.95% |
| 5-year return | +9.92% | +177.53% |
| P/E ratio (TTM) | 111.32 | — |
| Forward P/E | 18.01 | — |
| EPS (TTM) | $0.22 | $-1.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | — |
| Revenue growth (YoY) | +91.34% | — |
| Net income (latest FY) | $-16.14M | $-103.69M |
| Gross margin | 90.24% | — |
| Operating margin | -3.25% | — |
| Net margin | -4.29% | — |
| 52-week high | $31.77 | $62.32 |
| 52-week low | $19.30 | $14.79 |
| Distance from 52-week high | -22.91% | -34.80% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +51.08% | +81.32% |
| Average volume | 2.23M | 1.12M |
| Shares outstanding | 125.69M | 73.27M |
| Employees | 354 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELVN has outperformed ARQT by 84.6 percentage points over the past year.
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
ARQT vs ELVN FAQ
Which is bigger, Arcutis Biotherapeutics or Enliven Therapeutics?
Arcutis Biotherapeutics (ARQT) is larger, with a market capitalization of $3.08B compared with $2.98B for Enliven Therapeutics (ELVN).
Which stock has performed better over the past year, ARQT or ELVN?
ELVN returned +99.95% over the past 12 months, compared with +15.30% for ARQT (price return, excluding dividends). Past performance does not predict future results.
Are Arcutis Biotherapeutics and Enliven Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.